|drug32||1: discontinuation of RAS blocker therapy Wiki||1.00|
|drug46||2: continuation of RAS blocker therapy Wiki||1.00|
|D002318||Cardiovascular Diseases NIH||0.17|
There is one clinical trial.
Sars-Cov2 has been found in the digestive tract, as well as the respiratory tract. Protection of health care workers during surgery has been increased and some guidelines advocate for abandoning laparoscopy in COVID19 patients for fear of contamination, evenghtough this does not benefit the patient. However, Sars-Cov2 contamination risk during visceral surgery remains unknown. Inadequate protection is unnecessary costful and can be inefficient if too binding. Our hypotheses are that 1) Sars-Cov 2 can travel through droplet and air during visceral surgery. 2) Laparoscopy, because of the pneumoperitoneum and its leaks, warrant more air contamination whereas laparotomy warrant more droplet contamination, which would justified increased protection.
Description: Composite criteria: "50cm above the operating site" and/or "1m50 from the operating site" and/or "3m from the operating site"Measure: Air contamination Time: 10 minutes after incision if no opening of the digestive lumen, or 10 minutes after opening of the digestive tract
Description: Cartography of Sars-Cov2 environment surface contaminationMeasure: Environment contamination Time: At the end of surgery, an average 1 hour 30 min
Description: Composite criteria: air contamination or environment contamination positivity rate according to surgical approach (laparoscopy or laparotomy)Measure: Surgical approach Time: At the end of the intervention, an average 2 hours
Description: Composite criteria: air contamination or environment contamination positivity rate according to opening of digestive tract status (opened or not)Measure: Opening of the digestive tract Time: At the end of the intervention,an average 2 hours
Description: Cartography of Sars-Cov2 presence in biological fluids (blood, stools, peritoneal fluid, digestive fluids, sputum, bile)Measure: Biological fluids Time: During the procedure, an average 2 hours 30 min
Description: Presence of Sars-Cov 2 in pneumoperitoneum, evaluated on surgical smoke filterMeasure: Pneumoperitoneum Time: At the end of the procedure,an average 2 hours 30 min
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports